Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adaptimmune Therapeutics PLC (ADAPY : OTC)

• Company Description    Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. Number of Employees: 272

• Price / Volume Information    Yesterday's Closing Price: $0.03 Daily Weekly Monthly 20 Day Moving Average: 492,668 shares Shares Outstanding: 265.05 (millions) Market Capitalization: $7.74 (millions) Beta: 0.90 52 Week High: $0.35 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.78% -29.30% 12 Week 192.00% 184.00% Year To Date 12.31% 19.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 99 PARK DRIVE MILTON PARK - ABINGDON,X0 OX14 4RY GBR ph: 44-12-3543-0000 fax: 44-12-3543-0001 ir@adaptimmune.com http://www.adaptimmune.com

• General Corporate Information    Officers Adrian Rawcliffe - Chief Executive Officer and Director David M. Mott - Chairman of the Board of Director William Bertrand - Chief Operating Officer Gavin Wood - Chief Financial Officer Andrew Allen - Director Peer Information Adaptimmune Therapeutics PLC (CORR.) Adaptimmune Therapeutics PLC (RSPI) Adaptimmune Therapeutics PLC (CGXP) Adaptimmune Therapeutics PLC (BGEN) Adaptimmune Therapeutics PLC (GTBP) Adaptimmune Therapeutics PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00653A107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 265.05 Most Recent Split Date: (:1) Beta: 0.90 Market Capitalization: $7.74 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.24 Price/Cash Flow: - Price / Sales: 0.12 EPS Growth vs. Year Ago Period: -140.74% vs. Previous Quarter: 38.89% Sales Growth vs. Year Ago Period: -89.33% vs. Previous Quarter: 87.74% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - - 12/31/25 - - Current Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - 2.04 Quick Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - 2.04 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - -1,316.78 Book Value 06/30/26 - - 03/31/26 - - 12/31/25 - 0.12 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - 0.00 Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - 0.00

Powered by Zacks Investment Research ©